Monitoring of long steel pipes using acoustic emission

This thesis relates to the condition monitoring of long steel pipes using acoustic emission (AE). A number of experiments were carried out on pipes with a range of internal and external environments using a linear axial array of sensors with the ultimate aim of locating and reconstituting the time-domain and frequency-domain signatures of AE sources. The AE waves were generated from simulated, discontinuous, continuous, and semi-continuous sources and from real sources generated by impacts and crack propagation. The simulated source work in different internal and external environments was carried out to develop a generic empirical approach to AE propagation in long steel pipes which acknowledges the distortion of a source disturbance in the time and frequency domains. Generally, the acquired signals have two identifiable components and methods are developed for separating these components automatically and determining their group velocities. A simple model for attenuation is also developed which includes effects brought about by burial of the pipe and /or the nature of the fluid transported (liquid or gas). In the impact and crack extension tests a variety of intensities were simulated and the effect of type and intensity on time- and frequency-domain characteristics of the source was determined. The overall outcome is the demonstration of the potential of AE for identifying the nature, intensity and location of damaging events, such as crack growth and denting, and for the location and intensity assessment of leaks

Computational fluid dynamics study of dusty air flow over NACA 63415 airfoil for wind turbine applications

Gulf and South African countries have enormous potential for wind energy. However, the emergence of sand storms in this region postulates performance and reliability challenges on wind turbines. This study investigates the effects of debris flow on wind turbine blade performance. In this paper, two-dimensional incompressible Navier-Stokes equations and the transition SST turbulence model are used to analyze the aerodynamic performance of NACA 63415 airfoil under clean and sandy conditions. The numerical simulation of the airfoil under clean surface condition is performed at Reynolds number 460×103, and the numerical results have a good consistency with the experimental data. The Discrete Phase Model has been used to investigate the role sand particles play in the aerodynamic performance degradation. The pressure and lift coefficients of the airfoil have been computed under different sand particles flow rates. The performance of the airfoil under different angle of attacks has been studied. Results showed that the blade lift coefficient can deteriorate by 28% in conditions relevant to the Gulf and South African countries sand storms. As a result, the numerical simulation method has been verified to be economically available for accurate estimation of the sand particles effect on the wind turbine blades

Performance analysis of wells turbine blades using the entropy generation minimization method

Wells turbine concept depends on utilizing the oscillating air column generated over marine waves to drive a turbine. As a matter of fact, previous researches on the performance analysis of such turbine were based on the first law of thermodynamics only. Nonetheless, the actual useful energy loss cannot be completely justified by the first law because it does not distinguish between the quantity and the quality of energy. Therefore, the present work investigates the second law efficiency and entropy generation characteristics around different blades that are used in Wells turbine under oscillating flow conditions. The work is performed by using time-dependent CFD models of different NACA airfoils under sinusoidal flow boundary conditions. Numerical investigations are carried out for the incompressible viscous flow around the blades to obtain the entropy generation due to viscous dissipation. It is found that the value of second law efficiency of the NACA0015 airfoil blade is higher by approximately 1.5% than the second law efficiency of the NACA0012, NACA0020 and NACA0021 airfoils. Furthermore, it is found that the angle of attack radically affects the second law efficiency and such effect is quantified for NACA0015 for angle of attack ranging from -15° to 25°

Performance of a Wind Turbine Blade in Sandstorms Using a CFD-BEM Based Neural Network

In arid regions, such as the North African desert, sandstorms impose considerable restrictions on horizontal axis wind turbines (HAWTs), which have not been thoroughly investigated. This paper examines the effects of debris flow on the power generation of the HAWT. Computational Fluid Dynamics (CFD) models were established and validated to provide novel insight into the effects of debris on the aerodynamic characteristics of NACA 63415. To account for the change in the chord length and Reynolds number along the span of the blade and the 3D flow patterns, the power curves for a wind turbine were obtained using the Blade Element Momentum (BEM) method. We present a novel coupled application of the neural network, CFD, and BEM to investigate the erosion rates of the blade due to different sandstorm conditions. The proposed model can be scaled and developed to assist in monitoring and prediction of HAWT blade conditions. This work shows that HAWT performance can be significantly diminished due to the aerodynamic losses under sandstorm conditions. The power generated under debris flow conditions can decrease from 10 to 30% compared to clean conditions

Rethinking justice beyond human rights. Anti-colonialism and intersectionality in the politics of the Palestinian Youth Movement

This article discusses the politics of the Palestinian Youth Movement (PYM) – a contemporary social movement operating across a number of Arab and western countries. Unlike analysis on the Arab Uprisings which focused on the national dimension of youth activism, we explore how the PYM politics fosters and upholds an explicitly transnational anti-colonial and intersectional solidarity framework, which foregrounds a radical critique of conventional notions of self-determination based on state-framed human rights discourses and international law paradigms. The struggle becomes instead framed as an issue of justice, freedom and liberation from interlocking forms and hierarchies of oppression. KEYWORDS: Palestine, transnational social movements, intersectionality, human rights, anti-colonialis

RAGE and Modulation of Ischemic Injury in the Diabetic Myocardium

OBJECTIVE—Subjects with diabetes experience an increased risk of myocardial infarction and cardiac failure compared with nondiabetic age-matched individuals. The receptor for advanced glycation end products (RAGE) is upregulated in diabetic tissues. In this study, we tested the hypothesis that RAGE affected ischemia/reperfusion (I/R) injury in the diabetic myocardium. In diabetic rat hearts, expression of RAGE and its ligands was enhanced and localized particularly to both endothelial cells and mononuclear phagocytes

Evaluating the SERCA2 and VEGF mRNAs as Potential Molecular Biomarkers of the Onset and Progression in Huntington's Disease

Abnormalities of intracellular Ca2+ homeostasis and signalling as well as the down-regulation of neurotrophic factors in several areas of the central nervous system and in peripheral tissues are hallmarks of Huntington\u2019s disease (HD). As there is no therapy for this hereditary, neurodegenerative fatal disease, further effort should be made to slow the progression of neurodegeneration in patients through the definition of early therapeutic interventions. For this purpose, molecular biomarker(s) for monitoring disease onset and/or progression and response to treatment need to be identified. In the attempt to contribute to the research of peripheral candidate biomarkers in HD, we adopted a multiplex real-time PCR approach to analyse the mRNA level of targeted genes involved in the control of cellular calcium homeostasis and in neuroprotection. For this purpose we recruited a total of 110 subjects possessing the HD mutation at different clinical stages of the disease and 54 sex- and agematched controls. This study provides evidence of reduced transcript levels of sarco-endoplasmic reticulum-associated ATP2A2 calcium pump (SERCA2) and vascular endothelial growth factor (VEGF) in peripheral blood mononuclear cells (PBMCs) of manifest and premanifest HD subjects. Our results provide a potentially new candidate molecular biomarker for monitoring the progression of this disease and contribute to understanding some early events that might have a role in triggering cellular dysfunctions in HD

Tixagevimab–cilgavimab for treatment of patients hospitalised with COVID-19: a randomised, double-blind, phase 3 trial

Background: Tixagevimab–cilgavimab is a neutralising monoclonal antibody combination hypothesised to improve outcomes for patients hospitalised with COVID-19. We aimed to compare tixagevimab–cilgavimab versus placebo, in patients receiving remdesivir and other standard care. Methods: In a randomised, double-blind, phase 3, placebo-controlled trial, adults with symptoms for up to 12 days and hospitalised for COVID-19 at 81 sites in the USA, Europe, Uganda, and Singapore were randomly assigned in a 1:1 ratio to receive intravenous tixagevimab 300 mg–cilgavimab 300 mg or placebo, in addition to remdesivir and other standard care. Patients were excluded if they had acute organ failure including receipt of invasive mechanical ventilation, extracorporeal membrane oxygenation, vasopressor therapy, mechanical circulatory support, or new renal replacement therapy. The study drug was prepared by an unmasked pharmacist; study participants, site study staff, investigators, and clinical providers were masked to study assignment. The primary outcome was time to sustained recovery up to day 90, defined as 14 consecutive days at home after hospital discharge, with co-primary analyses for the full cohort and for participants who were neutralising antibody-negative at baseline. Efficacy and safety analyses were done in the modified intention-to-treat population, defined as participants who received a complete or partial infusion of tixagevimab–cilgavimab or placebo. This study is registered with ClinicalTrials.gov, NCT04501978 and the participant follow-up is ongoing. Findings: From Feb 10 to Sept 30, 2021, 1455 patients were randomly assigned and 1417 in the primary modified intention-to-treat population were infused with tixagevimab–cilgavimab (n=710) or placebo (n=707). The estimated cumulative incidence of sustained recovery was 89% for tixagevimab–cilgavimab and 86% for placebo group participants at day 90 in the full cohort (recovery rate ratio [RRR] 1·08 [95% CI 0·97–1·20]; p=0·21). Results were similar in the seronegative subgroup (RRR 1·14 [0·97–1·34]; p=0·13). Mortality was lower in the tixagevimab–cilgavimab group (61 [9%]) versus placebo group (86 [12%]; hazard ratio [HR] 0·70 [95% CI 0·50–0·97]; p=0·032). The composite safety outcome occurred in 178 (25%) tixagevimab–cilgavimab and 212 (30%) placebo group participants (HR 0·83 [0·68–1·01]; p=0·059). Serious adverse events occurred in 34 (5%) participants in the tixagevimab–cilgavimab group and 38 (5%) in the placebo group. Interpretation: Among patients hospitalised with COVID-19 receiving remdesivir and other standard care, tixagevimab–cilgavimab did not improve the primary outcome of time to sustained recovery but was safe and mortality was lower. Funding: US National Institutes of Health (NIH) and Operation Warp Speed

3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial

Background Liraglutide 3\ub70 mg was shown to reduce bodyweight and improve glucose metabolism after the 56-week period of this trial, one of four trials in the SCALE programme. In the 3-year assessment of the SCALE Obesity and Prediabetes trial we aimed to evaluate the proportion of individuals with prediabetes who were diagnosed with type 2 diabetes. Methods In this randomised, double-blind, placebo-controlled trial, adults with prediabetes and a body-mass index of at least 30 kg/m2, or at least 27 kg/m2 with comorbidities, were randomised 2:1, using a telephone or web-based system, to once-daily subcutaneous liraglutide 3\ub70 mg or matched placebo, as an adjunct to a reduced-calorie diet and increased physical activity. Time to diabetes onset by 160 weeks was the primary outcome, evaluated in all randomised treated individuals with at least one post-baseline assessment. The trial was conducted at 191 clinical research sites in 27 countries and is registered with ClinicalTrials.gov, number NCT01272219. Findings The study ran between June 1, 2011, and March 2, 2015. We randomly assigned 2254 patients to receive liraglutide (n=1505) or placebo (n=749). 1128 (50%) participants completed the study up to week 160, after withdrawal of 714 (47%) participants in the liraglutide group and 412 (55%) participants in the placebo group. By week 160, 26 (2%) of 1472 individuals in the liraglutide group versus 46 (6%) of 738 in the placebo group were diagnosed with diabetes while on treatment. The mean time from randomisation to diagnosis was 99 (SD 47) weeks for the 26 individuals in the liraglutide group versus 87 (47) weeks for the 46 individuals in the placebo group. Taking the different diagnosis frequencies between the treatment groups into account, the time to onset of diabetes over 160 weeks among all randomised individuals was 2\ub77 times longer with liraglutide than with placebo (95% CI 1\ub79 to 3\ub79, p<0\ub70001), corresponding with a hazard ratio of 0\ub721 (95% CI 0\ub713\u20130\ub734). Liraglutide induced greater weight loss than placebo at week 160 (\u20136\ub71 [SD 7\ub73] vs 121\ub79% [6\ub73]; estimated treatment difference 124\ub73%, 95% CI 124\ub79 to 123\ub77, p<0\ub70001). Serious adverse events were reported by 227 (15%) of 1501 randomised treated individuals in the liraglutide group versus 96 (13%) of 747 individuals in the placebo group. Interpretation In this trial, we provide results for 3 years of treatment, with the limitation that withdrawn individuals were not followed up after discontinuation. Liraglutide 3\ub70 mg might provide health benefits in terms of reduced risk of diabetes in individuals with obesity and prediabetes. Funding Novo Nordisk, Denmark